Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 21Parkinson Disease 4, Autosomal Dominant Lewy Body 15Carcinoma, Renal Cell 7Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Melanoma 2von Hippel-Lindau Disease 1Thyroid Neoplasms 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Kidney Neoplasms 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Differentiated Thyroid Cancer (DTC) 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Advanced Malignancies 1Advanced Endometrial Cancer 1

Interventions

trametinib 1lenvatinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Differentiated Thyroid Cancer (DTC) × lenvatinib × Clear all
NCT02966093 2022-01-26

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Eisai Inc.

Phase 3 Completed
151 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡